Universität zu Köln

Ehlken, Nicola, Verduyn, Cora, Tiede, Henning, Staehler, Gerd, Karger, Gabriele, Nechwatal, Robert, Opitz, Christian F., Klose, Hans, Wilkens, Heinrike, Rosenkranz, Stephan, Halank, Michael and Gruenig, Ekkehard (2014). Economic Evaluation of Exercise Training in Patients with Pulmonary Hypertension. Lung, 192 (3). S. 359 - 367. NEW YORK: SPRINGER. ISSN 1432-1750

Full text not available from this repository.

Abstract

Exercise training as an add-on to medical therapy has been shown to improve exercise capacity, quality of life, and possibly prognosis in patients with pulmonary hypertension (PH). The purpose of this study was to analyze the impact of exercise training on healthcare costs in PH. Estimated healthcare costs have been compared between patients with severe PH under optimized medical therapy only (control group) versus patients who received exercise training as an add-on to medical therapy (training group). Cost-analysis included a cost-estimation model of costs for baseline and follow-up visits and all PH-related healthcare events that occurred within the follow-up period. Time to clinical worsening and survival were assessed by clinical records, phone, and/or control visits. At baseline, the training (n = 58) and control group (n = 48) did not differ in age, gender, WHO-functional class, 6-min walking distance, hemodynamic parameters, or PH-targeted medication. During a follow-up of 24 +/- A 12 months, the training group had significantly better survival rates at 1 and 3 years and less worsening events (death, lung transplantation, hospitalization due to PH, new PAH-targeted medication) than the control group (15 vs. 25 events, p < 0.05), which also led to lower estimated healthcare costs of 657a,not sign within a period of 2 years. This is the first study to investigate the cost-effectiveness of exercise training in PH. Due to less worsening events within 2 years, healthcare costs were lower in patients performing exercise training as add-on to medical therapy than in patients with medical treatment only. Further prospective, randomized studies are needed to confirm these findings.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ehlken, Nicola UNSPECIFIED UNSPECIFIED UNSPECIFIED Verduyn, Cora UNSPECIFIED UNSPECIFIED UNSPECIFIED Tiede, Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Staehler, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Karger, Gabriele UNSPECIFIED UNSPECIFIED UNSPECIFIED Nechwatal, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Opitz, Christian F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Klose, Hans UNSPECIFIED UNSPECIFIED UNSPECIFIED Wilkens, Heinrike UNSPECIFIED UNSPECIFIED UNSPECIFIED Rosenkranz, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Halank, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Gruenig, Ekkehard UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-437252
DOI:	10.1007/s00408-014-9558-9
Journal or Publication Title:	Lung
Volume:	192
Number:	3
Page Range:	S. 359 - 367
Date:	2014
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-1750
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHRONIC HEART-FAILURE; COST-EFFECTIVENESS ANALYSIS; QUALITY-OF-LIFE; ARTERIAL-HYPERTENSION; CAPACITY; THERAPY; DISEASE Multiple languages Respiratory System Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43725